These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2174 related items for PubMed ID: 10223338

  • 21. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM, McKeating JA, de Souza JB, Roitt IM, Delves PJ, Lund T.
    Virology; 1998 Nov 10; 251(1):59-70. PubMed ID: 9813203
    [Abstract] [Full Text] [Related]

  • 22. Influence of polypeptide size and intracellular sorting on the induction of epitope-specific CTL responses by DNA vaccines in a mouse model.
    Wild J, Bojak A, Deml L, Wagner R.
    Vaccine; 2004 Apr 16; 22(13-14):1732-43. PubMed ID: 15068857
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Hemagglutinating virus of Japan protein is efficient for induction of CD4+ T-cell response by a hepatitis B core particle-based HIV vaccine.
    Takeda S, Shiosaki K, Kaneda Y, Nakasatomi T, Yoshizaki H, Someya K, Konno Y, Eda Y, Kino Y, Yamamoto N, Honda M.
    Clin Immunol; 2004 Jul 16; 112(1):92-105. PubMed ID: 15207786
    [Abstract] [Full Text] [Related]

  • 27. Strong synergistic effects of multicomponent vaccine for human immunodeficiency virus infection.
    Okuda K, Kaneko T, Yamakawa T, Tanaka S, Hamajima K, Shigematsu T, Yamamato A, Kawamoto S.
    J Clin Lab Immunol; 1993 Jul 16; 40(3):97-113. PubMed ID: 7877154
    [Abstract] [Full Text] [Related]

  • 28. Polygene DNA vaccine induces a high level of protective effect against HIV-vaccinia virus challenge in mice.
    Shinoda K, Xin KQ, Jounai N, Kojima Y, Tamura Y, Okada E, Kawamoto S, Okuda K, Klinman D, Okuda K.
    Vaccine; 2004 Sep 09; 22(27-28):3676-90. PubMed ID: 15315847
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Preclinical studies on immunogenicity of the HIV-1 p17-based synthetic peptide AT20-KLH.
    Fiorentini S, Marini E, Bozzo L, Trainini L, Saadoune L, Avolio M, Pontillo A, Bonfanti C, Sarmientos P, Caruso A.
    Biopolymers; 2004 Sep 09; 76(4):334-43. PubMed ID: 15386266
    [Abstract] [Full Text] [Related]

  • 31. Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope.
    Haglund K, Forman J, Kräusslich HG, Rose JK.
    Virology; 2000 Mar 01; 268(1):112-21. PubMed ID: 10683333
    [Abstract] [Full Text] [Related]

  • 32. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
    Chakraborty K, Durani V, Miranda ER, Citron M, Liang X, Schleif W, Joyce JG, Varadarajan R.
    Biochem J; 2006 Nov 01; 399(3):483-91. PubMed ID: 16827663
    [Abstract] [Full Text] [Related]

  • 33. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting.
    Richmond JF, Mustafa F, Lu S, Santoro JC, Weng J, O'Connell M, Fenyö EM, Hurwitz JL, Montefiori DC, Robinson HL.
    Virology; 1997 Apr 14; 230(2):265-74. PubMed ID: 9143282
    [Abstract] [Full Text] [Related]

  • 34. A universal T cell epitope-containing peptide from hepatitis B surface antigen can enhance antibody specific for HIV gp120.
    Greenstein JL, Schad VC, Goodwin WH, Brauer AB, Bollinger BK, Chin RD, Kuo MC.
    J Immunol; 1992 Jun 15; 148(12):3970-7. PubMed ID: 1376346
    [Abstract] [Full Text] [Related]

  • 35. Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope.
    Zolla-Pazner S, Cohen SS, Krachmarov C, Wang S, Pinter A, Lu S.
    Virology; 2008 Mar 15; 372(2):233-46. PubMed ID: 18061228
    [Abstract] [Full Text] [Related]

  • 36. Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses.
    Martin SJ, Vyakarnam A, Cheingsong-Popov R, Callow D, Jones KL, Senior JM, Adams SE, Kingsman AJ, Matear P, Gotch FM.
    AIDS; 1993 Oct 15; 7(10):1315-23. PubMed ID: 8267904
    [Abstract] [Full Text] [Related]

  • 37. Different immune response of mice immunized with conjugates containing multiple copies of either consensus or mixotope versions of the V3 loop peptide from human immunodeficiency virus type 1.
    Cruz LJ, Iglesias E, Aguilar JC, Cabrales A, Reyes O, Andreu D.
    Bioconjug Chem; 2004 Oct 15; 15(5):1110-7. PubMed ID: 15366967
    [Abstract] [Full Text] [Related]

  • 38. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L, Zolla-Pazner S, Gorny MK, Cheng-Mayer C.
    Virology; 1997 Mar 17; 229(2):360-9. PubMed ID: 9126249
    [Abstract] [Full Text] [Related]

  • 39. Libraries of human rhinovirus-based HIV vaccines generated using random systematic mutagenesis.
    Resnick DA, Smith AD, Zhang A, Geisler SC, Arnold E, Arnold GF.
    AIDS Res Hum Retroviruses; 1994 Mar 17; 10 Suppl 2():S47-52. PubMed ID: 7865333
    [Abstract] [Full Text] [Related]

  • 40. A disulfide-bound HIV-1 V3 loop sequence on the surface of human rhinovirus 14 induces neutralizing responses against HIV-1.
    Zhang A, Geisler SC, Smith AD, Resnick DA, Li ML, Wang CY, Looney DJ, Wong-Staal F, Arnold E, Arnold GF.
    Biol Chem; 1999 Mar 17; 380(3):365-74. PubMed ID: 10223339
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 109.